Effective inactivated vaccines to control Japanese encephalitis (JE) have been developed but they are expensive and require repeated booster vaccinations. Several attempts have been made to develop a live attenuated JE virus vaccine (Rohitayodhin & Hammon, 1962; Kodama et al., 1968; Takehara et al., 1969; Yu et al., 1973) . The most promising attenuated JE virus vaccine is the Chinese SA14-14-2 virus derived from the wild-type strain SA14 (Yu et al., 1973) . The safety and efficacy of this vaccine have been confirmed in human vaccinees (Yu et al., 1981 Ao et al., 1983) .
The JE virus SA14 strain was isolated from mosquitoes collected in Sian, China, in 1954 (Li, 1986 . The first attenuated variant, 12-1-7, was obtained after passage of the virulent parent virus SA14 11 times by intracerebral inoculation of newborn mice, followed by 100 passages in primary hamster kidney (PHK) cells (Yu et al., 1962; Li, 1986) . Passage histories of the SA14 attenuated viruses are summarized in Fig. 1 . The SA14-2-8 virus was
The nucleotide sequence data presented here have been submitted to the GenBank database and assigned the accession numbers U02367 (SA14-2-8), U04521 (SA14-5-3), and U04522 (SA14/USA). attenuated by irradiation of 12-1-7 virus with ultraviolet light followed by plaque purification. SA14-5-3 virus was derived from 12-1-7 virus by additional plaque purification passages in PHK cells. SA14-14-2/PHK virus was obtained by a further passage of the SA14-5-3 virus in suckling mice and by plaque purification in PHK cells (Yu et al., 1981 ; Li, 1986) . Eckels et al. (1988) passaged SA14-14-2/PHK virus nine times in primary dog kidney (PDK) cells to prepare the SAI4-14-2/PDK vaccine. All of these candidate vaccine strains are attenuated for humans and are not encephalitogenic in adult mice inoculated intracerebrally with 106 p.f.u, of virus (Chen & Wang, 1974; Yu et al., 1981 ; Wills et al., 1992) .
JE virus is a member of the Flavivirus genus. It has a positive-sense ssRNA genome, approximately 11 kb in length, which encodes three structural proteins, capsid (C), membrane (M) and envelope (E) and seven nonstructural proteins (Brinton, 1986) . The flavivirus C protein forms the structural component of the nucleocapsid. It elicits no neutralizing antibody and has groupreactive antigenic determinants (Chambers et al., 1990) . The M protein is a component of the virus envelope and is believed to interact with the cell surface and elicit neutralizing activity (Brinton, 1986; Heinz, 1986 protein contains the viral haemagglutinin. It induces protective immunity and mediates receptor-specific virus attachment to the cell surface (Brinton, 1986) . This protein plays a major role in the pathogenicity of the virus by determining the cellular tropism and/or affecting virus penetration into susceptible cells (Gollins & Porterfield, 1984; Heinz, 1986) .
The molecular basis of JE virus attenuation has not been elucidated, although genomes of both the virulent parental strain SA14 and the attenuated vaccine viruses SA14-14-2/PHK (Aihara et al., 1991) and SA14-14-2/PDK (Nitayaphan et al., 1990) have been sequenced and compared. The nucleotide sequences of SA14 published by the two groups are not identical and nucleotide differences between parent and attenuated viruses SA 14-14-2/PHK or SA 14-14-2/PDK were identified throughout the genome. Aihara et al. (1991) found 57 nucleotide changes, coding for 24 amino acid substitutions, between SA14 (referred to here as SA14/ JAP) and SA14-14-2/PHK. Nitayaphan et al. (1990) reported 45 nucleotide changes, coding for 15 amino acid substitutions, between SA14 (referred to here as SA14/ CDC) and SA14-14-2/PDK viruses. Both groups reported that most of the amino acid substitutions were present in the virus structural proteins.
Unfortunately the initial attenuated clone of SA14 virus, 12-1-7, no longer exists. Therefore to elucidate the molecular basis of the attenuation of JE virus, we cloned and sequenced the 5' non-coding region and structural protein genes of attenuated vaccine viruses SA 14-2-8 and SA14-5-3. Since the published nucleotide sequence of SA14/CDC differed from SA14/JAP the structural protein genes of the parent SA14 virus (referred to here as SA14/USA) were again cloned and sequenced. The nucleotide and deduced amino acid sequences of SA14-5-3 and SA14-2-8 viruses were compared to the published sequences of the two SA14-14-2 attenuated vaccine strains and that of wild-type parental SA14. The biological, antigenic and immunogenic properties of vaccine strains SA14-2-8, SA14-5-3 and SA14-14-2 have been described previously. It has been shown that all of these viruses are attenuated for mice Wills et al., 1992 Wills et al., , 1993 and these viruses were used in the studies reported here.
JE viruses were grown in mosquito C6/36 cells and viral RNA was extracted as previously described (Chomczynski & Sacchi, 1987; Jennings et al., 1993) . Four sense oligonucleotide primers (covering nucleotides 1 to 34, 8 to 28, 895 to 916 and 1276 to 1303) and four antisense primers (nucleotides 1298 to 1317, 1180 to 1201, 2463 to 2483 and 3453 to 3477) were designed on the basis of the published SA14 genomic sequence (Nitayaphan et al., 1990) . Viral RNA was reverse-transcribed, converted into cDNA and sequenced using published methods (Nitayaphan et al., 1990; Lewis et al., 1992; Jennings et al., 1993) . Computer analyses of nucleic acid sequence information and deduced amino acid sequences were accomplished using the MICROGENIE (Queen & Korn, 1984) and CLUSTAL (Higgins & Sharp, 1988) programs.
Comparison of the nucleotide sequence of SA14/USA with that of the SA14/CDC sequence reported by Nitayaphan et al. (1990) revealed differences at positions 1052 (G to A), 1708 (G to A), 1921 (C to U), 2293 (A to G) and 2441 (G to A). These resulted in three amino acid differences at positions E244 (glutamic acid to glycine), E315 (alanine to valine) and E439 (lysine to arginine) of the E protein (Table 1, Fig. 2) . Sequences of the SA14/USA and SA14/JAP (Aihara et al., 1991) viruses differed by four nucleotides at positions 1052, 1217, 1708 and 1977, which introduced two amino acid differences at positions 244 (glutamic acid to glycine) and 334 (proline to serine) of the E protein (Table 1) . These sequence differences are presumably due to the passage history of the SA14 virus used in the three studies. SA14/USA was a mouse brain preparation of SA14 virus whereas SA14/CDC was a plaque-purified virus, derived from the mouse brain preparation containing SA14/USA virus following three passages in PDK cell culture (Eckels et al., 1988; Nitayaphan et al., 1990) . SA14/JAP virus was derived by plaque purification of SA14 virus in baby hamster kidney (BHK)-21 cells (Aihara et al., 1991) . Since these three preparations of All four vaccine viruses had the same amino acid residues as those of SA14/CDC at E315 and E439. Amino acids in bold type refer to common substitutions shared by the four vaccine strains.
SA14-5-3 differed from SA14/USA virus by 15 nucleotides and eight amino acids over the 5' non-coding region and structural protein genes. SA14-2-8 virus differed from its parent virus (SA14/USA) by 13 nucleotides and eight amino acids. These amino acid substitutions occurred at positions E126, E128, E138, E176, E179, E244, E315 and E439. Of the nucleotide differences present in the SA14-2-8 virus, substitutions at positions 1052 (E25), 1061 (E28), 1389 (E138), 1503 (E176), 1708 (E244), 1921 (E315) and 2293 (E439) were present at the same positions in the other attenuated JE virus vaccine strains (Table 1) . Nucleotide changes at positions 1052 and 1061 did not result in amino acid substitutions. Nucleotide 1708 in SA14-5-3 virus was the same as that present in the SA14/JAP virus at this position. SA14-14-2/PHK, SA14-14-2/PDK and SA14-5-3 vaccine viruses have seven identical amino acid substitutions compared with the sequences of the SA14/USA and SA14/JAP viruses. These included one in the C protein (C65) and six in the E protein (E107, E138, E176, E279, E315 and E439; Table 1 and Fig. 2 ). When the amino acid sequence of the SA14-2-8 virus was included in the comparison, four common amino acid substitutions were found (Table 1 and Fig. 2 ). These were at positions E138 (glutamic acid to lysine), E176 (isoleucine to valine), E315 (alanine to valine) and E439 (lysine to arginine). These attenuated JE vaccine viruses shared two common amino acids with the virulent SA14/CDC virus at positions E315 and E439. This suggests that these two amino acids are not involved in the attenuated phenotype.
Comparison of 5' non-coding region and structural protein genes of four vaccine strains and wild-type JE virus strains revealed only two common amino acid substitutions, E138 and E176, in the vaccine strains. Nucleotide variations at positions 1354, 1360, 1512, 1661 and 2051 of SA14-2-8 virus resulted in three unique amino acid substitutions in the SA14-2-8 virus at positions E126, E128 and E179. The 13 nucleotide and nine amino acid differences between SA14-2-8 and SA 14-14-2/PHK viruses presumably resulted from the ultraviolet light irradiation treatment of SA14-2-8 virus and the subsequent 13 animal passages and six plaque purifications. The unique nucleotide difference at position 576 of SA14-5-3 virus did not result in an amino acid substitution.
The deduced amino acid sequences of the parent SA14 virus and the attenuated derivative viruses were analysed by the Novotny method (Novotny & Auffray, 1984) , which calculates hydrophobicity and can be used to predict protein conformation and any changes in secondary structure. This program predicted that the amino acid substitution at position E138 (glutamic acid to lysine) would cause a change in the charged residues profile and alpha-helix propensity of the E proteins of the attenuated viruses compared with parental SA14. Amino acid substitution at C65 of SA14-14-2/PHK, SA14-14-2/PDK and SA14-5-3 vaccine viruses would change the hydrophobicity profile and beta-sheet propensity of the C protein secondary structure.
A unique difference was noted in the SA14-14-2/PDK virus at amino acid 243 in the E protein, where lysine was present instead of glutamic acid in all other JE virus strains (data not shown). Haemagglutination (HA) assays using different strains of JE virus showed that the optimum pH for agglutination of gander red blood cells was 6-0 , whereas SA14-14-2/PDK virus had a much broader optimum pH range (6.0 to 6.2; data not shown). It is possible that the lysine residue at E243 is involved in determining the optimum pH for the HA activity of the SA14-14-2/PDK virus.
Monoclonal antibody (MAb) reactivities of the wildtype parental SAI4 and attenuated vaccine derivatives have been compared. E protein antigenic changes among the attenuated viruses have been found to be identical . By indirect immunofluorescence and HA inhibition tests, two E-protein reactive MAbs (T60 and V23), prepared against SA14-5-3 virus, recognized only vaccine strains derived from SA14 (SA14-14-2/PHK, SA14-14-2/PDK, SA14-2-8 and SA14-5-3). Five E-protein reactive MAbs (K10, K13, K24, K43 and J44), prepared against wild-type JE viruses, did not react with any vaccine virus strains . This indicates that common E protein epitope(s) are present on all vaccine strains derived from SA14, possibly due to common amino acid change(s). This hypothesis has been investigated by comparing the sequences of the parental SA14 virus and four attenuated clones. All of the attenuated vaccine strains have two identical amino acid substitutions at positions E138 and E176 (Table 1) . Therefore, one or both amino acid substitutions in these clones could be responsible for the three-dimensional structure changes in the E protein that alter wild-typespecific epitopes and generate new vaccine-specific epitopes. The predicted change in secondary structure of the E protein caused by the glutamic acid to lysine substitution at position E138 supports this proposal.
The two common amino acid substitutions in the E protein at positions E138 and E176 may also contribute to attenuation. The attenuated viruses were found not to bind dopamine D2 and/or 5HT~ subtype receptors recognized by the antagonist ligand spiperone, whereas the wild-type virulent parent strain SA14 did (Barrett et al., 1991) . Infectious cDNA clones of JE virus must be used to determine whether or not these amino acid substitutions are directly involved in the attenuation of the vaccine virus.
